NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
20:44
Nicușor Dan warns that he will request a re-examination of the Decarbonization Law to protect the funds from the PNRR
20:28
Lionel Messi donated 80,000 euros for the reconstruction of the Sierra Oeste area near Madrid, devastated by fires.
20:16
UN: Acute child malnutrition reaches alarming levels in Afghanistan
20:00
Spider-Man: Brand New Day generated $1.05 billion in the first six days, becoming the second fastest grossing film after Avengers: Endgame
19:50
Timișoara and Oradea reduce public lighting to save energy
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
